IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

Highlight

– A first-in-human, open-label phase 1 study tested IL-10–expressing anti-CD19 CAR T cells in relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) to reduce inflammatory toxicity while maintaining anti-leukaemic activity.

– The intervention was feasible and produced early signals of clinical activity with potentially lower rates or severity of cytokine release syndrome (CRS) and neurotoxicity (ICANS) versus historical expectations, but the trial was small and non-randomised.